Kaitlyn M. Greer

Kaitlyn M. Greer

Auto-generated profile, based on publicly available information

Kaitlyn M. Greer

College of Pharmac University of Michigan Ann Arbor Michigan USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2025 in JMIR Cardio
Verified
Journal Article
Open access
MDMichael P Dorsch
Michael P Dorsch
AFAllen J Flynn
Allen J Flynn
KGKaitlyn M Greer
Kaitlyn M Greer
SGSabah Ganai
Sabah Ganai
GBGeoffrey D Barnes
Geoffrey D Barnes
BZBrian Zikmund-Fisher
Brian Zikmund-Fisher
Background: Atrial fibrillation (AF) is associated with an increased risk of stroke. Oral anticoagulation (OAC) is used for stroke prevention in AF, but it also increases bleeding risk. Clinical guidelines do not definitively recommend for or against OAC for patients with borderline stroke risk. Decision-making may benefit from values clarification exercises to communicate risk trade-offs. Objective: This study aimed to evaluate if a visual with a values clarification alters the understanding of the trade-offs of anticoagulation in AF. Methods: Participants aged 45‐64 years were recruited across the United States via an online survey. While answering the survey, they were asked to imagine they were newly diagnosed with AF with a CHA2DS2-VASc (congestive heart failure; hypertension; age ≥75 years [doubled]; type 2 diabetes; previous stroke, transient ischemic attack, or thromboembolism [doubled]; vascular disease; age 65 to 75 years; and sex category) score of 1 for men and 2 for women. Eligibility criteria included no diagnosis of AF and no prior OAC use. Participants were randomized to one of three conditions: (1) standard text-based information only (n=255), (2) visual aids showing stroke-risk probabilities (n=218), or (3) visual aids plus a values clarification exercise (visual+VC; n=200). Participants were subrandomized within the 2 visual-based groups to view either a gauge display or an icon array representing stroke risk. All participants read a hypothetical scenario of being newly diagnosed with AF and hypertension. The primary outcome was decision confidence as measured by the SURE (Sure of Myself; Understand Information; Risk-Benefit Ratio; Encouragement) test. Secondary measures included participants’ perceived stroke risk reduction, worry about stroke or bleeding, and likelihood to choose OAC. Results: A total of 673 participants completed the survey. The overall SURE test was 61.2% (156/255) for the standard, 66.5% (145/218) for the visual, and 67% (134/200) for the visual+VC group (visual vs standard P=.23; visual+VC vs standard P=.20). Participants were less likely to choose OAC in the visual groups (standard: mean 58.3, SD 30; visual: mean 51.4, SD 32; visual+VC: 51.9, SD 28; P=.03). Participants felt the reduction in stroke risk from an OAC was less in the visual groups (standard: mean 63.8, SD 22; visual: mean 54.2, SD 28; visual+VC: mean 58.6, SD 25; P<.001). Visualization methods (gauge vs icon array) showed no significant differences in overall SURE test results. Participants were less likely to choose OAC and perceived a smaller stroke risk reduction with gauge than icon array (OAC choice: gauge 48.8, icon array 55.4; P=.03; stroke risk reduction: gauge 52.1, icon array 60.4; P=.001). Conclusions: Visual aids can modestly affect decision confidence and perceptions regarding the benefits of OAC but do not significantly alter decision certainty in a scenario where the guidelines do not recommend for or against OAC. Future work should determine the role of a gauge versus icon array visual for decision-making in stroke prevention in AF.

18 January 2026 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
MAMohamed S. Ali
Mohamed S. Ali
KGKaitlyn M. Greer
Kaitlyn M. Greer
SGSabah Ganai
Sabah Ganai
TKTodd M. Koelling
Todd M. Koelling
SHScott L. Hummel
Scott L. Hummel
MDMichael P. Dorsch
Michael P. Dorsch
Aims: Guideline‐directed medical therapy (GDMT) implementation in heart failure with reduced ejection fraction (HFrEF) remains suboptimal. A computable algorithm was developed to generate a medication optimization score (MOS) and provide guideline‐based recommendations. This computable algorithm was previously validated using clinical trial data, and an updated version was developed in 2021 to include sodium‐glucose co‐transporter 2 inhibitors. This study evaluated the association between the medication optimization information generated by this version of the algorithm and clinical outcomes using real‐world data. Methods: We conducted a retrospective cohort study of 1352 ambulatory adult patients with chronic HFrEF who received care from the advanced heart failure service at the University of Michigan between July 1, 2021, and October 14, 2024. The algorithm‐generated MOS was calculated using electronic health record data. The primary outcome was a composite of all‐cause mortality or hospitalization. Cox proportional hazards models were used to evaluate the association between baseline MOS and the primary outcome. A time‐varying Cox model using the running cumulative MOS and a marginal structural model (MSM) was also conducted. A linear mixed‐effects model was used to assess improvement in MOS over time as the secondary outcome. Results: In the analysis adjusted for HF severity and comorbidities, baseline MOS was associated with a lower hazard of the composite outcome (hazard ratio (HR) 0.96, 95% confidence interval (95% CI): 0.92, 0.99, p = 0.040). In the cumulative time‐varying Cox model and the marginal structural model, the association with time‐varying MOS became stronger, with HRs of 0.88 (95% CI 0.81–0.95; p = 0.0015) and 0.88 (95% CI 0.83–0.93; p < 0.001), respectively. The event rates per 100 person‐years were 44.1 in MOS 0%–33%, 39.5 in MOS 34%–66%, and 31.8 in MOS 67%–100%. Longitudinally, MOS improved over time. Conclusion: Higher algorithm‐generated MOS values were significantly associated with lower all‐cause mortality or hospitalization, and the MOS values increased over the follow‐up period. This suggested that this algorithm effectively identifies opportunities for GDMT optimization in real‐world clinical settings.

14 November 2025 in JMIR Cardio
Verified
Journal Article
Open access
MAMohamed S Ali
Mohamed S Ali
BOBruna Oewel
Bruna Oewel
KGKaitlyn M Greer
Kaitlyn M Greer
SGSabah Ganai
Sabah Ganai
MNMark W Newman
Mark W Newman
MDMichael P Dorsch
Michael P Dorsch
Background: The management of heart failure (HF) requires complex, data-driven decision-making. Although electronic health record (EHR) systems and clinical decision support (CDS) tools can streamline access to essential clinical information, it remains unclear which EHR elements and tools cardiologists and general medicine physicians prioritize when caring for patients with HF. Objective: This study aims to identify these elements and tools to improve the user interface design of future EHR applications. Methods: This study used a user-centered design research approach to understand physician workflows and decision-making needs in HF care. A cross-sectional online survey was administered to 302 physicians, comprising 150 cardiologists (including 15 HF specialists) and 152 general medicine physicians. Respondents reported their use of EHR variables (eg, medication lists, laboratory results, diagnostic tests, problem lists, clinical notes) for decision-making in HF care, as well as their time spent in the EHR before, during, and after patient visits along with their use of predictive models and patient-reported outcome questionnaire. Descriptive analyses, χ 2 tests, and t tests were conducted to compare groups, with statistical significance set at P <.05. Results: A total of 302 health care providers participated in the survey, nearly evenly split between cardiologists (49.7%, 150/302) and general medicine physicians (50.3%, 152/302). Both groups consistently relied on medication lists, vital signs, laboratory results, diagnostic tests, problem lists, and clinical notes for HF decision-making. Cardiologists placed greater emphasis on diagnostic tests for inpatient HF care (mean [SD] overall frequency, 4.66 [0.50] vs 4.44 [0.64]; P =.012) and outpatient HF care (mean [SD] overall frequency, 4.67 [0.55] vs 4.35 [0.71], P <.001). In contrast, general medicine physicians relied more on problem lists for inpatient HF care (mean [SD] overall frequency, 4.63 [0.58] vs 4.43 [0.72], P =.034), with no significant difference in the outpatient setting ( P >.05). Both groups underutilized standardized questionnaires and predictive models, with only 20.1% (29/144) of cardiologists and 4.5% (6/133) of general medicine physicians using standardized questionnaires ( P <.001) Conclusions: Both physician groups depend on medication lists, laboratory results, diagnostic tests, and problem lists. Cardiologists prioritize diagnostic tests, whereas general medicine physicians more often use problem lists. Low use of questionnaires and predictive models highlights the need for better integration of these tools. Future EHR design interface should tailor functionalities to accommodate these differing priorities and optimize HF care.